Get in Touch
Have questions? Call or chat with our Patient Advocates for answers.
Written by Karen Selby, RN | Medically Reviewed By Dr. Andrea Wolf | Edited By Walter Pacheco | Last Update: June 27, 2024
Immune checkpoint inhibitors target specific proteins called antigens on the surface of cancer cells. In turn, the inhibitory effects of tumor cells on immune cells are minimized. This allows the immune system to control the cancer better.
Clinical trials are testing these innovative drugs to discover if they could play a role in the treatment of mesothelioma.
Of these immunotherapy drugs, Keytruda, Opdivo and Yervoy have been approved to treat pleural mesothelioma by the U.S. Food and Drug Administration (FDA). Additionally, several ongoing clinical trials could lead to further approval.
A 2021 clinical research study treated peritoneal mesothelioma patients with a nivolumab and ipilimumab combination. The disease control rate was over 65%. The median overall survival was 19.1 months, and 68% of patients survived for at least one year.
Mesothelioma research has shown that several immune checkpoint inhibitors are effective against asbestos-related cancer, especially Keytruda and the combination of Opdivo and Yervoy.
Checkpoint inhibitors are antibodies that block antigens on the surface of cancer cells or block proteins on immune cells called T cells. Antigens work like a mask to hide cancer cells from the immune system.
These antigens are also called immune checkpoints.
Drugs that inhibit checkpoint antigens effectively unmask cancer cells, allowing the immune system to recognize and attack the cancer.
The antigens that checkpoint inhibitors block include CTLA-4 and PD-L1.
Keytruda and Opdivo target PD-1, a checkpoint protein on the surface of T cells. PD-1 attaches to PD-L1. By preventing this interaction, T cells are not fooled into thinking cancerous cells are healthy, allowing for an immune response.
Out of all of these drugs, Keytruda is the most well-known. In 2015, former U.S. President Jimmy Carter said Keytruda put his malignant melanoma into remission.
Learn how to access mesothelioma clinical trials utilizing immunotherapy.
Sign Up NowImmune checkpoint inhibitors can cause side effects that are similar to other anti-cancer treatments, such as chemotherapy and radiation therapy.
While some immune checkpoint inhibitor side effects overlap with those of more conventional treatments, the underlying cause differs.
Chemotherapy and radiation affect both cancerous and normal tissue. They work because they are much more damaging to rapidly dividing cancer cells than normal cells.
Immune checkpoint inhibitors don’t damage cells directly. Instead, they allow immune cells to recognize cancer cells and destroy them.
Because these drugs “turn up” the immune system, they may also cause the immune system to attack healthy cells and organs. This can lead to serious side effects.
Access top mesothelioma cancer centers that have experience treating this rare disease.
Get Help NowThese serious side effects can occur in up to 30 percent of patients receiving checkpoint inhibitors. If they occur, they require immediate attention.
According to a 2018 Journal of the American Medical Association article, autoimmune complications of these therapies can affect various tissues and organs.
Autoimmune skin side effects are the most common, affecting up to 30 percent of people.
Typical treatments for skin issues include topical steroids and antihistamines for mild cases. Oral steroids can be used to manage more serious skin side effects.
Autoimmune colitis — an inflammation of the colon’s lining — occurs in approximately 25 percent of patients taking Yervoy and less than 5 percent of people receiving anti-PD-1 or anti-PD-L1 single-drug therapy.
This side effect can be life-threatening, so if you experience any changes in bowel habits, report this to your oncologist immediately.
Mild cases can be managed with hydration and anti-diarrheal medication. More severe cases always require oral steroids.
This differs from diarrhea because cytotoxic chemotherapy can be managed with oral hydration, electrolytes and antidiarrheal drugs.
Between 2 to 5 percent of people treated with immune checkpoint inhibitors experience life-threatening pneumonitis or inflammation in the lungs.
Symptoms of pneumonitis include a dry cough, shortness of breath and low blood oxygen levels (hypoxia). These side effects are similar to pleural mesothelioma symptoms.
If you experience changes in your breathing when taking an immune checkpoint inhibitor, tell your oncologist immediately.
The endocrine system includes glands that excrete hormones, which are found in many parts of the body. Symptoms of these autoimmune complications include fatigue, low blood pressure and headaches.
Endocrine complications typically are permanent and are managed with replacement hormones.
Immune checkpoint inhibitor complications involving the liver, heart and nervous system are rare.
Most mesothelioma clinical trials testing these drugs involve two immune checkpoint inhibitors. Combining drugs that target different antigens has a synergistic effect.
Some trials combine immune checkpoint inhibitors with chemotherapy or a mesothelioma vaccine.
Positive results from phase I and phase II trials of Yervoy and Opdivo in mesothelioma patients have led to a phase III clinical trial.
This is significant because phase III trials for mesothelioma are rare. It isn’t common for therapy to work well enough in a phase II mesothelioma trial to warrant further study. Researchers have high hopes for this study.
Trials of Imfinzi and tremelimumab in mesothelioma patients began in 2016 and 2017. These trials are too new to produce results.
However, in 2015, an Italian clinical trial that combined these drugs proved clinical activity in mesothelioma, which means the study proved these drugs are effective but did not prove whether the drugs improved survival.
In 2017, the Seattle Cancer Care Alliance opened a phase II clinical trial combining Imfinzi with cisplatin and pemetrexed chemotherapy drugs (Alitma).
In 2017, the Moffitt Cancer Center in Tampa, Florida, opened a phase II clinical trial combining Keytruda with the mesothelioma vaccine CRS-207. The trial is available at five other cancer centers in the U.S.
Recommended ReadingYour web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
Selby, K. (2024, June 27). Immune Checkpoint Inhibitors for Mesothelioma. Asbestos.com. Retrieved October 21, 2024, from https://www.asbestos.com/treatment/immunotherapy/checkpoint-inhibitors/
Selby, Karen. "Immune Checkpoint Inhibitors for Mesothelioma." Asbestos.com, 27 Jun 2024, https://www.asbestos.com/treatment/immunotherapy/checkpoint-inhibitors/.
Selby, Karen. "Immune Checkpoint Inhibitors for Mesothelioma." Asbestos.com. Last modified June 27, 2024. https://www.asbestos.com/treatment/immunotherapy/checkpoint-inhibitors/.
A medical doctor who specializes in mesothelioma or cancer treatment reviewed the content on this page to ensure it meets current medical standards and accuracy.
Please read our editorial guidelines to learn more about our content creation and review process.
Dr. Andrea Wolf is the Director of the New York Mesothelioma Program at Mount Sinai in New York City. She focuses on multidisciplinary treatment, clinical research, community outreach and education.
Mesothelioma Center - Vital Services for Cancer Patients & Families doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.